| Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis K Yau, KT Abe, D Naimark, MJ Oliver, J Perl, JA Leis, S Bolotin, V Tran, ... JAMA network Open 4 (9), e2123622-e2123622, 2021 | 52 | 2021 |
| Treatment of Ebola-related Critical Illness FRA Kiiza P, Mullin S, Teo K, Adhikari NK Intensive Care Medicine, 2020 | 28 | 2020 |
| Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis K Yau, CT Chan, KT Abe, Y Jiang, M Atiquzzaman, SI Mullin, E Shadowitz, ... Cmaj 194 (8), E297-E305, 2022 | 25 | 2022 |
| Efficacy of rituximab in treatment-resistant focal segmental glomerulosclerosis with elevated soluble urokinase-type plasminogen activator receptor and activation of podocyte … MA Hladunewich, D Cattran, SM Sethi, SS Hayek, J Li, C Wei, SI Mullin, ... Kidney international reports 7 (1), 68-77, 2022 | 16 | 2022 |
| Principles and practices of establishing a hospital-based Ebola treatment unit P Kiiza, NKJ Adhikari, S Mullin, K Teo, RA Fowler Critical care clinics 35 (4), 697-710, 2019 | 14 | 2019 |
| Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data S Mullin, BV Wyk, JL Asher, SR Compton, HG Allore, CJ Zeiss PNAS nexus 1 (3), pgac096, 2022 | 12 | 2022 |
| The humoral response to the BNT162b2 vaccine in hemodialysis patients K Yau, KT Abe, D Naimark, MJ Oliver, J Perl, JA Leis, S Bolotin, V Tran, ... medRxiv, 2021.05. 24.21257425, 2021 | 7 | 2021 |
| Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis. JAMA Netw Open 4: e2123622 K Yau, KT Abe, D Naimark, MJ Oliver, J Perl, JA Leis, S Bolotin, V Tran, ... | 5 | 2021 |
| Establishing Healthcare Worker Performance and Safety in Providing Critical Care for Patients in a Simulated Ebola Treatment Unit: Non-Randomized Pilot Study P Kiiza, SI Mullin, K Teo, L Goodman, A Perez, R Pinto, K Thompson, ... Viruses 13 (11), 2205, 2021 | 2 | 2021 |
| Chemical Entity Normalization for Successful Translational Development of Alzheimer’s Disease and Dementia Therapeutics S Mullin, R McDougal, KH Cheung, H Kilicoglu, A Beck, CJ Zeiss Research Square, 2023 | 1 | 2023 |
| Différences d’immunogénicité des vaccins anti-SRAS-CoV-2 mRNA-1273 (Moderna) et BNT162b2 (Pfizer-BioNTech) chez les patients dialysés K Yau, CT Chan, KT Abe, Y Jiang, M Atiquzzaman, SI Mullin, E Shadowitz, ... CMAJ 194 (21), E751-E760, 2022 | | 2022 |
| The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients (preprint) K Yau, KT Abe, DMJ Naimark, MJ Oliver, J Perl, JA Leis, S Bolotin, V Tran, ... | | 2021 |
| Establishing Feasibility and Safety of Providing Critical Care for Patients with Ebola through Design of a Simulated Ebola Treatment Unit P Kiiza, S Mullin, K Teo, A Perez, D Piquette, J Lee, K Thompson, R Kao, ... Critical Care Canada Forum 2018 66 (S1), 53, 2019 | | 2019 |
| Pregnancy Outcomes in Women on Intensive Hemodialysis Compared to Renal Transplant Recipients. SA-PO1130 H D'Souza, Rohan & Bhasin, Arrti & A, Gonzalez & Zaffar, Nusrat & S, Mullin ... American Society of Nephrology 27 (11), 899, 2016 | | 2016 |
| Network PPM. K Yau, KT Abe, D Naimark, MJ Oliver, J Perl, JA Leis, S Bolotin, V Tran, ... | | |
